Humanized antibodies

US10603367B2 · kind B2 · utility

Assignee

• PROBIODRUG AG · DE

Inventors

• Martin Kleinschmidt · Halle (Saale), DE
• Jens-Ulrich Rahfeld · Lieskau, DE
• Anke Piechotta · Bodenwerder, DE
• Stephan Schilling · Halle (Saale), DE
• Stephen D. Gillies · Carlisle, US

Key dates

• Filing date: Jan 10, 2018
• Grant date: Mar 31, 2020
• Expiry date: Jan 10, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/2821
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (Aβ N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of Aβ N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.